IL10 and inflammatory bowel disease: Further studies are now needed to assess the prevalence of anti-IL-10 in IBD across the life course and its relationship to diverse disease phenotypes, (for example age at onset, disease progression, disease activity measures, surgical history, extra-intestinal manifestations, and response to therapy).